GLP-1 drugs and sleep apnea: what they do and don't do

GLP-1 receptor agonists (such as liraglutide or tirzepatide) have changed the conversation about obstructive sleep apnea in people with obesity. But lowering the apnea index does not mean they are always the most effective option, or the right one for every patient. Here I explain what they achieve, where they fall short and how they fit with other treatments.

How they act on sleep apnea

These drugs were developed for diabetes and obesity. Their benefit in sleep apnea comes mainly through weight loss: less fat around the upper airway and neck usually means less collapse during sleep. You can read more in the guide on Ozempic, tirzepatide and sleep apnea.

That is why they are a weight treatment with an effect on apnea, not a treatment aimed at the spot that obstructs. It is like lowering the temperature of a room: it helps overall, but it does not fix a door that closes badly.

What the studies show

A 2025 meta-analysis of six studies and 1,067 participants found an average AHI reduction of about 9.5 events per hour, together with weight loss of almost 11 kg [1]. This is a real benefit, but variability between studies was very high, so that average cannot be applied to an individual person.

Another 2025 meta-analysis, of three randomized trials in adults with obesity and no diabetes, saw a larger reduction versus placebo (about 16.6 events per hour). The confidence interval was very wide, from 5.3 to 27.9 [2]. In that same analysis, adverse events were more frequent with the drug than with placebo [2].

Lowering the AHI on average does not mean normalizing it in every patient. An average drop can still leave someone with significant apnea.

Not every drug and not every patient responds the same way

In the pooled analysis, tirzepatide lowered the AHI more than liraglutide (about 21.9 versus 5.1 events per hour) [1]. These are indirect comparisons across different studies, not a head-to-head trial, and should be read with caution.

The patient profile also mattered. People with obesity improved more than those without it [1]. In people with type 2 diabetes the effect was smaller, about 5.7 events per hour, and in obesity without diabetes the authors describe a trend that needs more evidence because results were inconsistent [3].

What they do not solve on their own

Four limitations are worth keeping in mind:

• They do not act on the point of obstruction: if there is a nasal, palate or tongue problem, it may persist.
• They depend on staying on treatment: long-term studies on how long the benefit lasts and on safety are lacking.
• They have adverse effects: whether they are tolerable has to be weighed.
• They do not suit every profile: the evidence centers on people with obesity or diabetes.

For that reason, after losing weight, repeating a sleep study is advisable to know how much apnea remains and whether another treatment is needed.

How they fit with CPAP, oral appliances and surgery

The evidence I work with has no trial comparing these drugs directly with CPAP or surgery, so it is not possible to say which is "more effective" in general. What we do know is that CPAP remains the reference treatment, although poor adherence has driven the search for alternatives [2].

If you want to compare these alternatives calmly, the guide on CPAP, oral appliance or surgery goes into detail. To see where each person's airway collapses, drug-induced sleep endoscopy (DISE) is used, which helps choose the treatment.

An individualized and combined approach

Current recommendations point away from "one treatment for everyone". In a person with obesity, the usual order is to start with lifestyle and then consider GLP-1 drugs or bariatric surgery, with continued follow-up.

That does not rule out combining: a person can lose weight and, at the same time, use CPAP, an oral appliance or consider surgery if the apnea persists. What matters is the result in each patient, measured with a sleep study.

When to seek medical advice

This text is informational and does not replace a medical assessment. If you snore, have breathing pauses, daytime sleepiness, or are considering a weight-loss drug, the sensible step is to confirm the diagnosis first with a sleep study. You can start with the assessment.

The decision about the drug belongs to the medical team managing your obesity or diabetes. The sleep specialist then checks the state of the airway and treats the apnea that remains.